Xiaoli Zhang
Research Subjects
Research Interests
Xiaoli Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chengshi Quan
The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, Jilin 130021, China
1 shared publication - Minlan Yang
Department of Pathology, School of Medicine, Yangtze University, Jingzhou, China
1 shared publication - Peiye Song1 shared publication
- Shuai Zhao1 shared publication
- Ting Zhang
The Key Laboratory of Pathobiology, Ministry of Education, Bethune Medical College, Jilin University, Changchun, Jilin, China
1 shared publication - Xiangshu Jin
Department of Obstetrics and Gynecology, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 17 July 2017
- Published by MDPI AG in Preprints.org
Screening for Target Genes of CLDN6 in Breast Cancer Cell Line MCF-7 using Microarray Technology
Claudin-6 (CLDN6), one of CLDNs family which as the important component of tight junctions (TJs). CLDN6 function as a tumor suppressor in breast cancer as we declared before, whereas the molecular mechanism of CLDN6 on suppressing malignant phenotype of breast cancer is unclear. Gene expression profiling was used to investigate target genes of CLDN6 and the mechanism involved in malignant phenotypes of breast cancer cell line MCF-7. In three clones of CLDN6 over-expressed MCF-7 cells (MCF-7(CLDN6)), 54 up-regulated and 24 down-regulated genes were detected. Gene Ontology (GO) analysis revealed that differential expressed genes in MCF-7(CLDN6) clones mainly located on the membrane and nucleus, involved in metabolic processes, biological regulation, protein binding and cell communication. KEGG pathway enrichment analysis revealed that among the target genes and related pathways, three MCF-7(CLDN6) clones co-upregulated gene Stat4 and the other members of Jak/Stats signal pathway (Tyk2, Stat1, Stat3, Stat5a, Stat5b and Stat6) were up-regulated in the other two of MCF-7(CLDN6) clones, which have been participate in the signal transduction pathway in cancer. MTT assay, wound healing assay and invasion assay showed that inhibiting the Tyk2/Stats signal pathway with the tyrosine kinase inhibitor AG490 partially reversed the effect of CLDN6 on proliferation, migration and invasion of MCF-7 cells, besides, AG490 reversed expressions of EMT markers when CLDN6 overexpression brought, the data confirmed that, under the effect of high flux, gene expression profiling can be used as a means to study genes affected by CLDN6, and to screen the key regulatory genes involved in breast cancer.
- 17 July 2017
- Published by MDPI AG in Preprints.org
Open AccessScreening for Target Genes of CLDN6 in Breast Cancer Cell Line MCF-7 using Microarray Technology
Claudin-6 (CLDN6), one of CLDNs family which as the important component of tight junctions (TJs). CLDN6 function as a tumor suppressor in breast cancer as we declared before, whereas the molecular mechanism of CLDN6 on suppressing malignant phenotype of breast cancer is unclear. Gene expression profiling was used to investigate target genes of CLDN6 and the mechanism involved in malignant phenotypes of breast cancer cell line MCF-7. In three clones of CLDN6 over-expressed MCF-7 cells (MCF-7(CLDN6)), 54 up-regulated and 24 down-regulated genes were detected. Gene Ontology (GO) analysis revealed that differential expressed genes in MCF-7(CLDN6) clones mainly located on the membrane and nucleus, involved in metabolic processes, biological regulation, protein binding and cell communication. KEGG pathway enrichment analysis revealed that among the target genes and related pathways, three MCF-7(CLDN6) clones co-upregulated gene Stat4 and the other members of Jak/Stats signal pathway (Tyk2, Stat1, Stat3, Stat5a, Stat5b and Stat6) were up-regulated in the other two of MCF-7(CLDN6) clones, which have been participate in the signal transduction pathway in cancer. MTT assay, wound healing assay and invasion assay showed that inhibiting the Tyk2/Stats signal pathway with the tyrosine kinase inhibitor AG490 partially reversed the effect of CLDN6 on proliferation, migration and invasion of MCF-7 cells, besides, AG490 reversed expressions of EMT markers when CLDN6 overexpression brought, the data confirmed that, under the effect of high flux, gene expression profiling can be used as a means to study genes affected by CLDN6, and to screen the key regulatory genes involved in breast cancer.